Pharmacologic treatment of schizoaffective disorder
Authors:
- 1 May 1994
- journal article
- review article
- Published by Springer Nature in Psychopharmacology
- Vol. 114 (4) , 529-538
Abstract
In contrast to the considerable systematic study of the pharmacologic treatment of schizophrenia and mood disorders, the pharmacologic treatment of schizoaffective disorder has been relatively ignored. The authors reviewed the available literature regarding the pharmacologic treatment of schizoaffective disorder. The total number of controlled studies of the acute and prophylactic treatment of schizoaffective disorder was small and few used modern criteria to define the disorder. In studies of schizoaffective disorder, bipolar type (manic), lithium and antipsychotics produced comparable albeit incomplete responses, except in highly agitated patients when antipsychotics exerted superior efficacy. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone for schizoaffective, bipolar type patients. In the only controlled study of schizoaffective disorder, depressed type, the presumed superiority of combined antidepressant and antipsychotic treatment to antipsychotic alone was not found. Although combined antipsychotic and thymoleptic treatment represents common prophylactic management of schizoaffective disorder in clinical practice, the efficacy of this strategy has not been studied in controlled trials. Advances in the nosology of schizoaffective disorder, emerging epidemiologic data demonstrating large numbers of patients with this disorder in clinical populations, and preliminary evidence that clozapine may have combined antipsychotic and thymoleptic properties as well as efficacy in both the psychotic and affective components of schizoaffective disorder, suggest that renewed interest in the diagnosis and treatment of this disorder may lead to improved delivery of care for this understudied but seriously ill group of patients.Keywords
This publication has 76 references indexed in Scilit:
- The effect of long‐term lithium treatment on the mortality of patients with manic‐depressive and schizoaffective illness*Acta Psychiatrica Scandinavica, 1992
- Morbidity Risks of Schizophrenia and Affective Disorders among First-Degree Relatives of Patients with Schizoaffective DisordersThe British Journal of Psychiatry, 1991
- Unipolar and bipolar schizoaffective disorders: A comparative studyEuropean Archives of Psychiatry and Clinical Neuroscience, 1989
- A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year periodPsychopharmacology, 1989
- Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patientsLife Sciences, 1989
- Brain 5-HT2 receptor binding sites in depressed suicide victimsBrain Research, 1988
- Serotonin 5-HT2 receptor binding on blood platelets - a peripheral marker for depression?Life Sciences, 1987
- Different effects of serotonin antagonists on 3H-mianserin and 3H-ketanserin recognition sitesLife Sciences, 1985
- Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicidesNeuropharmacology, 1984
- Psychosis in Bipolar and Unipolar Affective Illness with Special Reference to Schizo-affective DisorderThe British Journal of Psychiatry, 1984